March 6, 2017
Mar 06, 2017
Elodie Sollier-Christen, Vortex Biosciences, was selected as the 2017 Innovation Award Winner at SLAS2017 in Washington, DC, for her presentation, Vortex Biosciences Technology for Fast and Label-Free Isolation of Circulating Tumor Cells from Blood Samples.
Vortex Biosciences has developed VTX-1, a fast and simple platform to isolate and collect intact circulating tumor cells (CTCs) directly from whole blood in less than 1.5 hours.
The team started with a technology developed in the lab of Professor Dino Di Carlo at UCLA. Vortex Biosciences was formed in 2012 to commercialize the technology.
In early 2014, Vortex and Accel Biotech formed a new collaboration to bring the system together for commercial launch. Accel Biotech brought to the collaboration their experience interfacing microfluidic cartridges to full instrument systems while Vortex Biosciences brought cell isolation technology.
Check out the presentation on the SLAS website or visit the Vortex Biosciences website for more information.
About Vortex Biosciences
The Vortex Biosciences mission is to be the innovation leader in CTC capture technology delivering diagnostic tests that improve therapeutic decisions and save lives.
About Accel Biotech
Accel Biotech, located in Northern California’s Silicon Valley, is a full-service contract development and manufacturing firm. Our mission at Accel Biotech is to pair our unique breadth of engineering and design experience in diagnostics, life sciences and disposables with a passion for quick development. We enable rapid prototyping with in-house machining, 3D printing and full production runs for complex devices. We value customer satisfaction above all else, seeking long-lasting relationships with our clients.